Some specificities in the management of hyperglycemia in patients with diabetic kidney disease

Tamara Dragović; Dejan M Marinković; Saša Kiković; Janko Pejović; Zoran Hajduković

doi:10.2298/VSP150321008D

Tamara Dragović Clinic of Endocrinology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Dejan M Marinković Clinic of Endocrinology, Military Medical Academy, Belgrade, Serbia,
Saša Kiković Clinic of Endocrinology, Military Medical Academy, Belgrade, Serbia,
Janko Pejović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institut of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia
Zoran Hajduković Clinic of Endocrinology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP150321008D

Keywords: hypoglycemic agents, renal insufficiency, chronic, diabetic nephropaties, insulin, blood glucose,

Abstract

References

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60(5): 850−86.

International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2013.

Centers for Disease Control and Prevention (CDC). Incidence of end -stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1997-2007. MMWR Morb Mortal Wkly Rep 2010; 59(42): 1361−6.

National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49(Suppl 2): S1−S180.

Molitch ME, Defronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79−S83.

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2004; 28(1): 164−76.

Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007; 27(2): 195−207.

Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuira and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24): 3272−7.

American Diabetes Association. Standards of Medical Care in Di-abetes - 2015. Diabetes Care 2015; 38(Suppl 1): S1−S93.

Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33(7): 1536−43.

The Diabetes Control and Complication Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993; 329(14): 977−86.

de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365(25): 2366−76.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854−65.

Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21−9.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on mi-crovascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376(9739): 419−30.

Patel A, Mcmahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560−72.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veter-ans with type 2 diabetes. N Engl J Med 2009; 360(2): 129−39.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 di-abetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European As-sociation for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364−79.

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, et al. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocr Pract 2013; 19(Suppl 2): 1−48.

Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic con-trol and cardiovascular events in diabetic hemodialysis pa-tients. Circulation 2009; 120(24): 2421−8.

Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY, et al. Glycated albumin and risk of death and hospitaliza-tions in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6(7): 1635−43.

Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M. Gly-cemic Control and the Risk of Death in 1,484 Patients Receiv-ing Maintenance Hemodialysis. Am J Kidney Dis 2010; 55(5): 875−84.

Saloranta C, Groop L, Ylinen K, Teramo K, Tolppanen EM, Tallgren LG. The usefulness of micro- and macrochromatographic de-terminations of glycohemoglobin in diabetic patients with nephropathy. Clin Nephrol 1986; 25(4): 186−92.

Vos FE, Schollum JB, Walker RJ. Glycated albumin is the pre-ferred marker for assessing glycaemic control in advanced chronic kidney disease. Clin Kidney J 2011; 4(6): 368−75.

Chen H, Wu T, Lin H, Jap T, Hsiao L, Lee S, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in di-abetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010; 55(5): 867−74.

Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18(3): 896−903.

Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 2008; 13(4): 278−83.

Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care 2012; 18(Suppl 1): S11−6.

Mitrakou A. Kidney: its impact on glucose homeostasis and hormonal regulation. Diabetes Res Clin Pract 2011; 93(Suppl 1): S66-72.

Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; 79(Suppl 120): S1−6.

Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacoki-netic properties of insulin in type 1 diabetic patients. Diabetes Care 2001; 24(5): 886−90.

Hasslacher C, Vogt C, Raupp D, Dreyhaupt J. Insulinbedarf bei Typ-1-Diabetikern mit nachlassender Nierenfunktion: Human-Insulin versus Analog-Insulin. Dtsch Med Wochenscher 2007; 132(47): 2500−4.

Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin. Ther Adv Endocrinol Metab 2013; 4(4): 113−21.

Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia: American College of Physicians; 1999.

Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insu-lin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60(5): 469−76.

Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Ob-es Metab 2008; 10(10): 811−23.

Campbell I. Oral antidiabetic drugs: their properties and rec-ommended use. Prescriber 2007; 18(6): 56−74.

Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011; 12(1): 57−69.

Nogueira C, Souto SB, Vinha E, Braga DC, Carvalho D. Oral glu-cose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones 2013; 12(4): 483−94.

Nye HJ, Herrington WG. Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease. Nephron Clin Pract 2011; 118(4): 380−3.

Home P, Mant J, Diaz J, Turner C. Management of type 2 di-abetes: summary of updated NICE guidance. BMJ 2008; 336(7656): 1306−8.

Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 4(Suppl 26): 73−85.

Palmer KJ, Brogden RN. Gliclazide. An update of its pharmaco-logical properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46(1): 92−125.

Cavanaugh KL. Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin Diabetes 2007; 25(3): 90−7.

Budde K, Neumayer H, Fritsche L, Sulowicz W, Stompôr T, Eckland D. The pharmacokinetics of pioglitazone in patients with im-paired renal function. Br J Clin Pharmacol 2003; 55(4): 368−74.

Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safe-ly and rapidly in Japanese type 2-diabetic patients on hemodia-lysis. Clin Nephrol 2007; 68(5): 287−94.

Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of ex-enatide. Br J Clin Pharmacol 2007; 64(3): 317−27.

Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic signific-ance through sodium glucose co-transporter 2 inhibitors. Me-tab Clin Exp 2014; 63(10): 1228−37.

Stanton RC. Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration: Is There a Role for SGLT2 Inhibitors in Diabetic Kidney Disease. Circulation 2013; 129(5): 542−4.

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159(4): 262−74.